Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study).
Picker N, Lee AY, Cohen AT, Maraveyas A, Beyer-Westendorf J, Mantovani LG, Abdelgawwad K, Fatoba S, Thate-Waschke IM, Bach M, Wilke T. Picker N, et al. Among authors: abdelgawwad k. Thromb Haemost. 2021 Feb;121(2):206-215. doi: 10.1055/s-0040-1714739. Epub 2020 Sep 2. Thromb Haemost. 2021. PMID: 32877956 Free PMC article.
Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism - The COSIMO study.
Cohen AT, Maraveyas A, Beyer-Westendorf J, Lee AYY, Folkerts K, Abdelgawwad K, De Sanctis Y, Fatoba S, Bamber L, Bach M, Mantovani LG; COSIMO Investigators. Cohen AT, et al. Among authors: abdelgawwad k. Thromb Res. 2021 Oct;206:1-4. doi: 10.1016/j.thromres.2021.06.021. Epub 2021 Jul 2. Thromb Res. 2021. PMID: 34332213 Free article. No abstract available.
Cancer-Associated ThrOmboSIs - Patient-Reported OutcoMes With RivarOxaban (COSIMO) - Baseline characteristics and clinical outcomes.
Maraveyas A, Beyer-Westendorf J, Lee AY, Mantovani LG, De Sanctis Y, Abdelgawwad K, Fatoba S, Bach M, Cohen AT. Maraveyas A, et al. Among authors: abdelgawwad k. Res Pract Thromb Haemost. 2021 Nov 30;5(8):e12604. doi: 10.1002/rth2.12604. eCollection 2021 Dec. Res Pract Thromb Haemost. 2021. PMID: 34877446 Free PMC article.
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism.
Coleman CI, Caroti KS, Abdelgawwad K, Psaroudakis G, Fatoba S, Rivera M, Schaefer B, Brobert G, Khorana AA, Becattini C, Lee AYY, Ekbom A, Carrier M, Brescia C, Cohen AT. Coleman CI, et al. Among authors: abdelgawwad k. JACC CardioOncol. 2023 Feb 7;5(2):189-200. doi: 10.1016/j.jaccao.2022.10.014. eCollection 2023 Apr. JACC CardioOncol. 2023. PMID: 37144109 Free PMC article.
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding.
Caroti KS, Becattini C, Carrier M, Cohen AT, Ekbom A, Khorana AA, Lee AYY, Brescia C, Abdelgawwad K, Psaroudakis G, Rivera M, Schaefer B, Brobert G, Coleman CI. Caroti KS, et al. Among authors: abdelgawwad k. TH Open. 2023 Jul 10;7(3):e206-e216. doi: 10.1055/s-0043-1770783. eCollection 2023 Jul. TH Open. 2023. PMID: 37435565 Free PMC article.
Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.
Caroti KS, Khorana AA, Becattini C, Lee AYY, Ekbom A, Carrier M, Cohen AT, Brescia C, Abdelgawwad K, Psaroudakis G, Rivera M, Schaefer B, Brobert G, Coleman CI. Caroti KS, et al. Among authors: abdelgawwad k. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231189282. doi: 10.1177/10760296231189282. Clin Appl Thromb Hemost. 2023. PMID: 37583314 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 35643716
17 results